Immunotherapy in older patients with cancer.
Ageing
Cancer
Elderly
Immunosenescence
Immunotherapy
Old people
Oncogeriatry
Journal
Biomedical journal
ISSN: 2320-2890
Titre abrégé: Biomed J
Pays: United States
ID NLM: 101599820
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
received:
12
03
2020
revised:
17
07
2020
accepted:
22
07
2020
pubmed:
13
10
2020
medline:
16
10
2021
entrez:
12
10
2020
Statut:
ppublish
Résumé
Ageing implicates a remodeling of our immune system, which is a consequence of the physiological senescence of our cells and tissues coupled with environmental factors and chronic antigen exposure. An immune system that senesces includes more differentiated cells with accumulation of highly differentiated CD4 and CD8 T cells. The pool of naive T cells decreases with the exponential thymic involution induced by age. Differentiated T cells have similar, if not higher, functional capacities but scarce studies are looking at the impact of senescence among specific T cells. After a stimulation, other immune cells (monocytes, dendritic cells and NK) are functionally altered during ageing. It is as if the immune system was more efficient at the basal level, but less efficient after a stimulation in the old compared to young people, likely due to less reserve. Concerning the clinical impact, older people are more prone to certain pathogens and their clinical manifestations differ from the younger people. Severe flu and VZV reactivation are more frequent with an altered cellular response to vaccination. Vaccination failure can have detrimental consequences in people presenting frailty criteria. Old people frailty is majored by their comorbidities and diseases like cancer. Thus, chemotherapies are employed with circumspection in older patients. The use of anti-PD-1/PD-L1 immunotherapies is therefore attractive, because of less side effects with a better response compared to chemotherapy. Old persons inclusion is lacking in current studies and clinical trials. Some subgroups or pooled analyses confirm the gain in response without increased toxicities in older patients but their inclusion criteria differ from the real-life practice. Specific studies focusing on this population are needed because of the increasing cancer incidence with age and the overall ageing of the population.
Identifiants
pubmed: 33041248
pii: S2319-4170(20)30126-8
doi: 10.1016/j.bj.2020.07.009
pmc: PMC8358190
pii:
doi:
Substances chimiques
Immunologic Factors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
260-271Informations de copyright
Copyright © 2020 Chang Gung University. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of interest The authors have no conflict of interest to declare.
Références
Nat Rev Immunol. 2019 Sep;19(9):563-572
pubmed: 31175337
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
CA Cancer J Clin. 2020 Mar;70(2):86-104
pubmed: 31944278
Interdiscip Top Gerontol. 2014;39:163-76
pubmed: 24862019
J Leukoc Biol. 2013 Apr;93(4):633-7
pubmed: 23341539
BMJ. 2014 Jul 08;349:g4227
pubmed: 25006006
Am J Clin Oncol. 2019 Feb;42(2):109-116
pubmed: 30300169
Cancer Treat Rev. 2016 Apr;45:30-7
pubmed: 26946217
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
Anticancer Res. 2005 Jul-Aug;25(4):3011-21
pubmed: 16080560
J Clin Oncol. 2016 Sep 1;34(25):2980-7
pubmed: 27354485
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Clin Cancer Res. 2018 Nov 1;24(21):5347-5356
pubmed: 29898988
J Geriatr Oncol. 2017 May;8(3):229-235
pubmed: 28223073
Gerontology. 2014;60(2):130-7
pubmed: 24296590
Nat Rev Drug Discov. 2020 Mar;19(3):163-164
pubmed: 32127660
Drugs Aging. 2019 Oct;36(10):927-938
pubmed: 31317421
Cancer Res. 2017 Mar 1;77(5):1075-1082
pubmed: 27872087
Trends Immunol. 2009 Jul;30(7):366-73
pubmed: 19540807
Eur J Cancer. 2018 Sep;100:126-134
pubmed: 30014881
Microbes Infect. 2010 Dec;12(14-15):1120-4
pubmed: 20849976
Cancer Immunol Immunother. 2018 Oct;67(10):1571-1578
pubmed: 30056599
Curr Mol Med. 2005 Mar;5(2):197-203
pubmed: 15974873
Nat Commun. 2017 May 24;8:15221
pubmed: 28537262
J Clin Invest. 2011 Aug;121(8):3109-19
pubmed: 21785218
N Engl J Med. 2018 May 17;378(20):1947-1948
pubmed: 29768155
J Clin Invest. 2011 Jun;121(6):2350-60
pubmed: 21555851
Lancet Oncol. 2017 Nov;18(11):1483-1492
pubmed: 28967485
J Geriatr Oncol. 2020 Jun;11(5):802-806
pubmed: 31948904
J Community Health. 2017 Apr;42(2):390-399
pubmed: 27900515
J Infect Dis. 2018 Sep 22;218(suppl_2):S88-S98
pubmed: 30247603
Sci Rep. 2020 Jan 9;10(1):80
pubmed: 31919463
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Am J Med Sci. 2014 Jul;348(1):65-70
pubmed: 24805784
Blood. 2002 Nov 15;100(10):3698-702
pubmed: 12393723
Aging (Albany NY). 2016 Feb;8(2):328-44
pubmed: 26878797
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Oncologist. 2012;17(11):1439-49
pubmed: 22941970
J Exp Clin Cancer Res. 2014 Apr 04;33:30
pubmed: 24708900
Proc Natl Acad Sci U S A. 2019 Nov 26;116(48):24242-24251
pubmed: 31719197
Nat Med. 2013 Apr;19(4):465-72
pubmed: 23455713
Med Pregl. 2011 Mar-Apr;64(3-4):183-7
pubmed: 21905597
Int J Cancer. 2020 Sep 15;147(6):1509-1518
pubmed: 31997345
Oncoimmunology. 2016 Oct 18;5(11):e1234572
pubmed: 27999751
Vaccine. 2019 Oct 8;37(43):6262-6267
pubmed: 31537443
J Infect Dis. 2015 Oct 15;212(8):1261-9
pubmed: 25828247
Clin Cancer Res. 2017 Apr 15;23(8):1920-1928
pubmed: 27827313
J Am Geriatr Soc. 2010 Aug;58(8):1565-75
pubmed: 20942872
J Thorac Oncol. 2019 Sep;14(9):1628-1639
pubmed: 31121324
Oncologist. 2017 Aug;22(8):963-971
pubmed: 28476944
Mech Ageing Dev. 2009 Nov-Dec;130(11-12):713-21
pubmed: 19744506
Semin Immunopathol. 2019 Jan;41(1):125-131
pubmed: 30006738
ESMO Open. 2017 Jul 3;2(2):e000213
pubmed: 28761757
J Immunol. 2019 Jan 15;202(2):476-483
pubmed: 30541882
Cancer Res. 1994 Dec 1;54(23):6243-8
pubmed: 7954473
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Ageing Res Rev. 2011 Jul;10(3):336-45
pubmed: 20619360
Nat Commun. 2019 Jun 3;10(1):2387
pubmed: 31160572
J Infect Dis. 2003 Nov 1;188(9):1336-44
pubmed: 14593591
N Engl J Med. 2017 Mar 16;376(11):1015-1026
pubmed: 28212060
Nat Immunol. 2017 Mar;18(3):354-363
pubmed: 28114291
Oncoimmunology. 2013 Dec 1;2(12):e27186
pubmed: 24498569
Blood. 2012 Oct 25;120(17):3455-65
pubmed: 22968455
J Clin Invest. 2014 Sep;124(9):4004-16
pubmed: 25083993
Cancer Treat Rev. 2017 Nov;60:60-68
pubmed: 28889085
Eur J Cancer. 2017 Sep;82:155-166
pubmed: 28689093
J Immunol. 2010 Mar 1;184(5):2518-27
pubmed: 20100933
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
BMC Cancer. 2015 Dec 28;15:1016
pubmed: 26711627
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
Clin Exp Immunol. 2020 May;200(2):141-154
pubmed: 31989585
Br J Cancer. 1994 May;69(5):911-3
pubmed: 8180022
Oncologist. 2019 Dec;24(12):e1351-e1359
pubmed: 31324663
Ann N Y Acad Sci. 2000 Jun;908:244-54
pubmed: 10911963
Int J Mol Sci. 2019 Mar 13;20(6):
pubmed: 30871268
Eur J Cancer. 2018 May;95:68-74
pubmed: 29635146
J Immunol. 2017 Aug 15;199(4):1405-1417
pubmed: 28696254
Oncoimmunology. 2015 Feb 25;4(4):e998538
pubmed: 26137416
Aging Cell. 2016 Feb;15(1):14-21
pubmed: 26472076
J Immunol. 2019 Apr 1;202(7):1962-1969
pubmed: 30737273
J Immunol Res. 2016;2016:8426874
pubmed: 27493973
Clin Infect Dis. 2012 Apr;54(7):922-8
pubmed: 22291101
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Clin Exp Immunol. 2018 Oct;194(1):79-92
pubmed: 30030847
J Immunother Cancer. 2018 Apr 4;6(1):26
pubmed: 29618381
Front Immunol. 2019 Aug 27;10:1965
pubmed: 31507593
Clin Nutr. 2015 Feb;34(1):79-85
pubmed: 24530027